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ORIGINAL INVESTIGATION

Use of imaging and clinical data
to screen for cardiovascular disease
in asymptomatic diabetics
Carlos Henrique Reis Esselin Rassi1†, Timothy W. Churchill2†, Carlos A. Fernandes Tavares1,
Mateus Guimaraes Fahel1, Fabricia P. O. Rassi1, Augusto H. Uchida1, Bernardo L. Wajchenberg1,
Antonio C. Lerario1, Edward Hulten3, Khurram Nasir4, Márcio S. Bittencourt3,5, Carlos Eduardo Rochitte1*
and Ron Blankstein3

Abstract
Background: There is increasing evidence to suggest that not all individuals with type 2 diabetes mellitus (T2DM)
have equal risk for developing cardiovascular disease. We sought to compare the yield of testing for pre-clinical atherosclerosis with various approaches.
Methods: 98 asymptomatic individuals with T2DM without known coronary artery disease (CAD) were enrolled in a
prospective study and underwent carotid ultrasound, exercise treadmill testing (ETT), coronary artery calcium (CAC)
scoring, and coronary computed tomography angiography (CTA).
Results: Of 98 subjects (average age 55 ± 6, 64 % female), 43 (44 %) had coronary plaque detectable on CTA, and
38 (39 %) had CAC score >0. By CTA, 16 (16 %) had coronary stenosis ≥50 %, including three subjects with CAC = 0.
Subjects with coronary plaque had greater prevalence of carotid plaque (58 % vs. 38 %, p = 0.01) and greater carotid
intima media thickness (0.80 ± 0.20 mm vs. 0.70 ± 0.11 mm, p = 0.02). Notably, 18 of 55 subjects (33 %) with normal
CTA had carotid plaque. Eight subjects had a positive ETT, of whom five had ≥ 50 % coronary stenosis, two had <50 %
stenosis, and one had no CAD. Among these tests, CAC scoring had the highest sensitivity and specificity for prediction of CAD.
Conclusion: Among asymptomatic subjects with T2DM, a majority (56 %) had no CAD by CTA. When compared to
CTA, CAC was the most accurate screening modality for detection of CAD, while ETT and carotid ultrasound were
less sensitive and specific. However, 33 % of subjects with normal coronary CTA had carotid plaque, suggesting that
screening for carotid plaque might better characterize stroke risk in such patients.
Keywords: Type 2 diabetes mellitus, Coronary artery disease, Coronary computed tomography angiography
Background
Cardiovascular disease is the leading cause of morbidity and mortality among individuals with type 2 diabetes
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mellitus (T2DM) [1–3], and diabetics have a higher risk
of cardiovascular disease as compared to non-diabetics
with a similar risk factor burden [4]. Moreover, once
individuals with diabetes present with a coronary heart
disease event, they experience a worse prognosis than
non-diabetics [5–8]. Unfortunately, diabetics are also
known to have a high burden of asymptomatic cardiovascular disease. Thus, a wide variety of clinical strategies
have been proposed for identifying diabetics with coronary artery disease (CAD) before it becomes clinically
manifest.

© 2016 Rassi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
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Although screening programs are currently employed
in asymptomatic diabetics in some clinical settings, their
potential capability to reduce the rate of adverse cardiac
outcomes remains unproven [9, 10]. In part, this may be
due to lower than anticipated event rates in clinical trials, as well as widespread use of preventive therapies irrespective of the screening strategy used [11]. While the
available studies to date support the use of preventive
therapies for most patients with diabetes, the yield and
optimal technique for risk stratifying lower-risk individuals with diabetes is uncertain. Despite the lack of proven
benefit, there may remain a role for screening selected
individuals with diabetes, particularly if the test results
could favorably influence downstream medical and lifestyle therapies. In addition, such screening approaches
could be useful to provide more individualized assessment when deciding on the intensity of statin therapy, the
role of aspirin [12], or potentially in the future, the role of
anti-inflammatory therapies [13] and newer lipid lowering agents [14].
Multiple imaging and laboratory techniques are available to detect the presence of pre-clinical disease and
consequently characterize an individual’s risk of future
cardiovascular events. However, it remains uncertain
how each of these approaches compare to each other and
to more expensive imaging techniques in the risk stratification of individuals with T2DM. Therefore, using coronary computed tomography angiography (CTA) as the
reference standard, we sought to compare the use of coronary artery calcium (CAC) scoring, carotid ultrasound,
and exercise treadmill testing (ETT) for detecting subclinical CAD among a cohort of asymptomatic patients
with diabetes.

Methods
Patient enrollment

In this prospective cohort study, 98 asymptomatic subjects with T2DM, as defined by American Diabetes Association criteria [15], were recruited between June 2011
and January 2013 from the Endocrinology Outpatient
Clinic of the University of São Paulo School of Medicine
Clinics Hospital. The Ethics Committee of the University
of São Paulo approved the study, and all patients provided informed consent during their initial visit.
We included individuals aged 40–65 years with a
known duration of diabetes of less than 10 years and
without known prior cardiovascular disease. Exclusion
criteria included a history of heart failure, ischemic heart
disease, chest pain, angina, arrhythmia, severe hypertension (blood pressure >180/100 mmHg), renal or hepatic
failure, dyspnea at rest, total cholesterol >350 mg/dL,
low-density lipoprotein (LDL) cholesterol >250 mg/dL,
triglycerides >500 mg/dL, body mass index (BMI) >45 kg/
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m2, known neoplasm, pregnancy, dementia, and an
allergy to iodinated contrast.
Power calculation [16, 17] estimates that a sample size
of 51 patients would be required for an α of 0.05 and
power of 0.8 in order to detect a difference among the
sensitivity of the three screening tests, assuming CAC
sensitivity to be 90 % [18, 19], ETT sensitivity 30 % [20],
and carotid ultrasound sensitivity 50 % [21, 22] for detection of any coronary plaque. ETT has highly variable
previously reported sensitivities for detection of obstructive CAD, but to screen for the presence of any plaque,
including non-obstructive, the sensitivity of ETT is lower
[20].
Clinical and laboratory evaluation

All clinical and historical data (e.g. diabetes duration)
were prospectively collected by a study physician prior to
all imaging and laboratory test results. Laboratory tests
included fasting glucose and glycosylated hemoglobin,
total cholesterol and cholesterol fractions, triglycerides,
creatinine, liver function tests, blood counts, and urine
and serum human chorionic gonadotropin β (in women
of childbearing age). Microalbuminuria was measured
using 24-hour urine collection.
Coronary CTA acquisition and analysis

Coronary CTA and CAC calcium scanning were performed using Toshiba Aquillion One scanner with 320
detectors, 0.5 mm slice thickness, with gantry rotation
of 350 ms. Scan coverage in the z-axis ranged from 12
to 16 cm. For the CTA acquisition, we used tube voltage between 80–135 kV and tube current between 200–
580 mA, both selected according to patient BMI. Prior
to each scan, the patient’s blood pressure and heart rate
were assessed, and if the heart rate was above 70 beats
per minute, beta-blockers were administered orally. Following oral beta blocker administration, if the heart rate
was greater than 64 bpm, intravenous metoprolol was
administered. We administered 70–100 mL of iodinated
contrast (Iopamiron 370 mg/ml; Bayer Schering Pharma,
Berlin, Germany) via an automated injector at a rate of
5 mL/second. The estimated mean radiation dose for the
complete CT protocol (coronary CTA plus CAC scanning) was 7.1 mSv per patient.
All coronary CTA images were transferred to a workstation (Vitrea FX—Vital Image) and analyzed by two
experienced cardiac imagers who were blinded to all
other data. A standard 18-segment coronary tree model
was used [23]. The calcium was calculated according to
the Agatston protocol [24].
CAD was defined by the presence of any atherosclerotic
plaque, which was defined as a tissue structure >1 mm2
that was contained within and/or adjacent to the coronary

Rassi et al. Cardiovasc Diabetol (2016) 15:28

artery lumen and could be clearly distinguished from the
vessel lumen [25]. Plaques were classified according to
the degree of luminal obstruction. Obstructive CAD was
defined as the presence of at least one plaque causing a
luminal reduction of more than 50 % [23]. In cases of a
disagreement between the two examiners, a third experienced cardiologist mediated a consensus.
Other testing modalities

In addition to CAC scoring and CTA analysis, all subjects
underwent exercise treadmill testing and carotid ultrasonography. Exercise treadmill tests were interpreted by
an experienced cardiologist who was blinded to all other
test results. When considering the exercise protocol,
42 % of subjects exercised using the Bruce protocol, and
52 % with the modified Bruce protocol. Of the remaining six subjects, five underwent test with Ellestad protocol and one with ramp protocol. The ECG was defined
as positive if there were horizontal or downsloping ST
depressions greater than 1 mm in two contiguous leads
(except aVR) 80 ms after the J-point. The ETT was considered non-diagnostic if subjects did not achieve 85 % of
the age predicted maximum heart rate.
Carotid ultrasounds were interpreted by an experienced radiologist. Carotid intima media thickness
(CIMT) was manually measured in both carotid arteries at end diastole over a 1 cm segment of the common
carotid artery located 0.5 cm below the carotid-artery
bulb [26]. CIMT ≥ 1 mm was defined as abnormal [27].
Carotid plaque was defined as a focal region protruding
into the vessel lumen that had either CIMT ≥ 1.5 mm or
focal wall thickening at least 50 % greater than that of the
surrounding vessel wall [28].
Statistical analysis

Continuous variables are presented as mean and standard
deviation or as median and quartiles, as appropriate, and
tested for significance using two-tailed t test or Kruskal–
Wallis test depending on whether the distribution was
normal. Categorical variables are presented as absolute
values and proportions and tested for significance with a
Chi squared test. To compare the diagnostic yield of various screening approached to detect CAD, we calculated
sensitivity and specificity for each test, using the presence of any disease by CTA as the reference standard. All
statistical analysis was done using Stata 12.1 (StataCorp,
College Station, Texas).

Results
Patient characteristics

Characteristics of study subjects are shown in Table 1,
stratified by the presence of any CAD. Mean age was
54.5 years, and 63 (63 %) of subjects were female. The
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mean hemoglobin A1c was 7.3 % and 22 (22 %) were on
insulin therapy. The mean LDL cholesterol was 116.7 mg/
dL. Fewer than 50 % of subjects were on statin therapy
or aspirin, and 50 (51 %) were on an ACE inhibitor or an
ARB. The median 10-year risk was 13.0 % as assessed by
Framingham Risk Score for coronary heart disease, 8.2 %
by the 2013 American Heart Association risk calculator, and 11.4 % by United Kingdom Prospective Diabetes
Study (UKPDS) risk engine.
Characteristics of patients with coronary artery disease

Subjects with coronary disease on coronary CTA were
more likely to be older and have hypertension, and
reported a longer duration of T2DM than subjects without CAD. Among laboratory parameters, only hemoglobin
A1c was significantly higher among those with CAD
on CTA. Insulin use was more common among those
with CAD. Similarly, use of cardiovascular medications,
including ACE inhibitors or ARBs and statins, was more
common in subjects with CAD. While there was a trend
towards increased aspirin use among those with CAD, this
did not reach statistical significance (p = 0.052).
Coronary CTA findings

Results of the coronary CTA are shown in Table 2. Overall, 55 subjects (56 %) had no CAD, while 27 (28 %) had
non-obstructive plaque (<50 % stenosis). The remaining
16 subjects (16 %) had at least one coronary stenosis over
50 %. Among the 43 subjects with any plaque, 27 (63 %)
had disease in multiple coronary vessels, and over one
third (16 subjects, or 37 %) had disease involving greater
than four coronary segments. Multivessel obstructive
disease (defined as greater than 50 % stenosis in more
than one coronary artery) was uncommon; only three
subjects had obstructive disease in two arteries and one
in all three arteries.
CAC findings

Overall, 60 subjects (61 %) did not have any CAC
(Table 2). Among the remaining 38 subjects with
CAC, the majority (24 subjects, or 63 %) had Agatston
score <100, with the remaining 14 (37 %) having an
Agatston score of 100 or greater.
Only five subjects had plaque on coronary CTA despite
a CAC of zero. The number of affected coronary segments in these subjects ranged from 1 to 5, and three of
the five individuals had stenosis greater than 50 %. Two
of these five subjects had carotid plaque, and one had a
positive ETT.
Results of carotid ultrasound and exercise treadmill testing

Results from carotid ultrasounds and ETT, stratified by
the presence of CAD, are presented in Table 3. Mean
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Table 1 Patient characteristics
All subjects
n = 98

Coronary artery
disease n = 43 (43.9 %)

No coronary artery
disease n = 55 (56.1 %)

p Value

Demographics
Age, years
Female sex (#, %)

54.5 ± 6.1

56.5 ± 5.8

63 (64.3 %)

24 (55.8 %)

53.0 ± 5.9

<0.01

39 (70.9 %)

0.12
0.03

Race (#, %)
Caucasian

64 (65.3 %)

33 (76.7 %)

31 (56.4 %)

Black

19 (19.4 %)

4 (9.3 %)

15 (27.3 %)

Asian

7 (7.1 %)

1 (2.3 %)

6 (10.9 %)

Other

8 (8.2 %)

5 (11.6 %)

3 (5.5 %)

Clinical data
Body mass index
Abdominal circumference, cm
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg

29.4 ± 4.7

29.5 ± 4.8

103.0 ± 12.1

105.0 ± 12.0

120.9 ± 17.2

125.3 ± 17.3

71.9 ± 11.9

73.9 ± 12.3

29.3 ± 4.7

101.4 ± 12.1

117.4 ± 16.5

70.3 ± 11.4

0.83
0.15
0.02
0.15

Treatment for hypertension (#, %)

64 (65.3)

34 (79.1 %)

30 (54.5 %)

Duration of diabetes, years

5.2 ± 3.3

6.5 ± 3.2

4.2 ± 3.0

<0.01

0.01

History of hyperlipidemia (#, %)

55 (56.1 %)

26 (60.5 %)

29 (52.7 %)

0.44

Family history of coronary artery disease (#, %)

10 (10.2 %)

7 (16.3 %)

3 (5.5 %)

0.08
0.74

Smoking status (#, %)
Current smoker

20 (20.4 %)

10 (23.3 %)

10 (18.2 %)

Former smoker

8 (8.2 %)

4 (9.3 %)

4 (7.3 %)

Never smoker

70 (71.4 %)

29 (67.4 %)

41 (74.5 %)

Framingham risk score (10-year estimated risk)
(median, interquartile range)

13.0 % (8.0–16 %)

13.0 % (10–20 %)

13.0 % (8–16 %)

0.07

2013 AHA/ACC risk calculator (10-year risk of
atherosclerotic cardiovascular disease)
(median, interquartile range)

8.2 % (4.0–16.0 %)

13.5 % (5.5–19.7 %)

7.0 % (2.3–13 %)

<0.01

UKPDS risk engine 10-year predicted risk of coronary
heart disease (median, interquartile range)

11.4 % (5.2–19.4 %)

17.9 % (11.7–26.2 %)

7.2 % (3.8–11.6 %)

<0.01

6.8 ± 1.5 %

<0.01

44.5 ± 12.5

0.44

Laboratory data
Hemoglobin A1c
Total cholesterol, mg/dL
HDL cholesterol, mg/dL
LDL cholesterol, mg/dL

7.3 ± 1.7 %

193.5 ± 39.7

45.5 ± 13.2

116.7 ± 35.1

8.0 ± 1.7 %

198.5 ± 46.6

46.7 ± 14.3

120.6 ± 41.4

189.7 ± 33.3

113.7 ± 29.2

0.28
0.33

Triglycerides, mg/dL (median, interquartile range)

133 (103–198)

148 (101–213)

129 (103–194)

0.46

Microalbuminuria, mg/24 h (median,
interquartile range)

5.8 (3.9–11.8)

8.1 (3.9–18.7)

5.4 (3.7–9.0)

0.09

Medications
Insulin use (#, %)

22 (22.5 %)

15 (34.8 %)

7 (12.7 %)

Oral hypoglycemic (#, %)

82 (83.7 %)

39 (90.7 %)

43 (78.2 %)

<0.01
0.10

ACE or ARB (#, %)

50 (51.0 %)

27 (62.8 %)

23 (41.8 %)

0.04

Statin (#, %)

45 (45.9 %)

25 (58.1 %)

20 (26.4 %)

0.03

Aspirin (#, %)

33 (33.7 %)

19 (44.2 %)

14 (25.5 %)

0.052

Values given are mean ± standard deviation unless otherwise specified

p Values were calculated using two-tailed t test and Chi squared test; Kruskal–Wallis test was used for comparison of medians

CIMT was greater in subjects with CAD. Similarly, a
greater proportion of subjects with CAD had carotid
plaque than those who did not have any CAD.

Only 8 (8 %) subjects had positive ECG changes during the exercise treadmill test, although 20 % of subjects
did not reach maximal predicted heart rate and one
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Table 2 Coronary computed tomography angiography
findings
Luminal stenosis on coronary CTA

Number of subjects (%)

No stenosis

55 (56.1)

1–24 %

13 (13.3)

25–49 %

14 (14.3)

50–69 %

7 (7.1)

70 % or greater
Number of coronary segments with plaque

9 (9.2)
Number of subjects (%)

0 segments

55 (56.1)

1–4 segments

27 (27.6)

5 or more segments
Number of coronary arteries with plaque

16 (16.3)
Number of subjects (%)

No plaque

55 (56.1)

1 vessel

16 (16.3)

2 vessels

15 (15.3)

3 vessels

12 (12.2)

Number of coronary arteries with obstructive
disease (≥50 % stenosis)

Number of subjects (%)

No obstructive disease

82 (83.7)

1 vessel

12 (12.2)

2 vessels

3 (3.1)

3 vessels
Coronary artery calcium (Agatston score)

1 (1.0)
Number of subjects (%)

0

60 (61.2)

1–99

24 (24.5)

100 or greater

14 (14.3)

subject had a non-diagnostic test due to baseline leftbundle branch block. Two patients had angina during the
exercise treadmill test. Of these, one had ECG changes
and considered as a positive test; the other had atypical
angina without ECG changes and was considered as a
negative test. The number of METS achieved during the
test did not differ between the CAD and the non-CAD
group (8.2 METs vs. 8.7 METS, p = 0.19), though subjects with CAD had a lower Duke Treadmill Score than
those without CAD (7.1 vs. 9.2, p = 0.03).
Predictive value of screening tests and historical
parameters for coronary artery disease

The sensitivity and specificity for each testing modality for the prediction of CAD are shown in Fig. 1. CAC
offered the best combination of sensitivity and specificity of any evaluated test to detect CAD. Carotid disease,
by contrast, was only modestly predictive of the presence
of coronary disease, with sensitivity and specificity in the
60 % range. ETT, in turn, was not sensitive, but had very
high specificity. Area under receiver operating characteristics (ROC) curves for these three modalities were 0.94
for CAC, 0.64 for carotid ultrasound, and 0.57 for ETT
(Fig. 1); p value was <0.01 for comparison of CAC with

other modalities, but was non-significant (0.29) for comparison of carotid ultrasound with ETT.
Test characteristics of evaluated historical parameters
are shown in Table 4. Of these, hypertension and hyperlipidemia were the most sensitive, while factors relating
to severity of diabetes—insulin use, poor glycemic control, and long duration of diabetes—all were relatively
insensitive but considerably more specific. Combinations
of these parameters yielded decreasing sensitivity and
increasing specificity.
The prevalence of CAD, stratified by insulin use and
subject age, is presented in Fig. 2. Among non-insulin dependent diabetics, younger subjects had a lower
prevalence of CAD. However, among insulin-dependent subjects, there was no significant difference in CAD
prevalence by age. The prevalence of CAD also increased
by duration of diabetes, as shown in Fig. 3.

Discussion
In this study of asymptomatic diabetic subjects without
known cardiovascular disease, we showed that there is a
substantial heterogeneity in the prevalence of subclinical
coronary disease, as only 44 % of subjects had evidence of
any plaque by coronary CTA and only 16 % had obstructive CAD. When coronary CTA was used as the reference
standard, CAC had the highest sensitivity for detection
of coronary plaque, while carotid ultrasound, exercise
treadmill testing, and risk factors, either alone or in combination, had lower sensitivity and specificity. Finally, we
also found that 33 % of the patients who did not have coronary plaque on CTA had atherosclerotic plaque involving the carotid arteries.
Prevalence of subclinical coronary disease

Perhaps more notable than the 44 % of subjects with
coronary disease is the fact that 56 % of the study participants had no atherosclerotic plaque in their coronary
arteries. Coronary CTA is a highly sensitive measure for
detection of CAD [29, 30], and subjects without plaque
on CTA correspondingly have a low rate of cardiovascular events and represent a low risk group [31–33]. This
finding demonstrates that there is considerable variability
in cardiac risk amongst diabetics and brings into question
the classification of diabetes as a coronary heart disease
equivalent [34]. As a risk stratification tool, screening
coronary CTA represents an efficient way to define a subset of diabetics at much lower risk for coronary heart disease, with a number needed to screen of two in order to
detect one low risk patient in our population. Nevertheless, further data are needed regarding the role of preventative therapies (or conversely safety of withholding such
therapies) in individuals who have T2DM without any
atherosclerosis on CTA [35, 36].
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Table 3 Results of screening tests stratified by the presence or absence of coronary artery disease
Screening tests

All subjects
(n = 98)

Subjects with coronary
artery disease (n = 43)

Subjects without coronary
artery disease (n = 55)

p Value

0

60 (61.0 %)

5 (11.6 %)

55 (100 %)

<0.01

≥ 1 (Agatston score)

38 (38.8 %)

38 (88.4 %)

0 (0 %)

Maximum intima medial thickness
(IMT), mm

0.75 ± 0.16

0.80 ± 0.20

0.70 ± 0.11

<0.01

IMT ≥ 1.0 mm (#, %)

11 (11.2 %)

11 (25.6 %)

0

<0.01

No carotid plaque

55 (56.1 %)

18 (41.9 %)

37 (67.3 %)

Carotid plaque

43 (43.9 %)

25 (58.4 %)

18 (32.7 %)

Carotid plaque or IMT ≥ 1.0 mm

44 (44.9 %)

26 (60.5 %)

18 (32.7 %)

<0.01

  Negative

69 (70.4 %)

26 (60.5 %)

43 (78.2 %)

0.04

  Positive

8 (8.2 %)

7 (16.3 %)

1 (1.8 %)

  Negative with <85 % MPHR

20 (20.4 %)

10 (23.3 %)

10 (18.2 %)

  Inconclusive due to LBBB

1 (1.0 %)

0

1 (1.8 %)

8.5 ± 2.1

8.2 ± 1.8

8.7 ± 2.4

Coronary artery calcium

Carotid artery ultrasound

Carotid plaque (#, %)
0.01

Exercise treadmill test

ECG test results (#, %)

Specific test outcomes
  METS
  Duke treadmill score

8.3 ± 4.8

7.1 ± 5.0

p Values calculated using two-tailed t test, Chi squared test, and Kruskal–Wallis test

9.2 ± 4.4

0.19
0.03

MPHR maximal predicted heart rate

Fig. 1 Sensitivity and specificity and area under receiver operating
characteristics curves of different screening modalities for detection
of coronary artery disease as diagnosed by CTA. CAC scoring was the
most sensitive and specific test for detection of CAD, with the greatest area under the ROC curve. Carotid atherosclerosis was defined as
presence of carotid plaque or CIMT ≥ 1 mm

The proportion of subjects with normal coronary arteries was greater in our population than in most published
series, which have reported prevalence rates of normal
CTA in individuals with diabetes ranging from 13–34 %
of subjects [31, 37–40]. Most published data, however,

pertain to subjects referred for coronary CTA, who had
either symptoms concerning for obstructive CAD or
an abnormal prior stress test. However, even when we
compared the prevalence of normal CTA in our study to
other screening populations of asymptomatic diabetics,
we observed a higher rate in our population. For example, in the FACTOR 64 trial, a large, multi-center study
of coronary CTA in asymptomatic diabetics, 31 % of subjects had a normal CTA. This difference likely reflects the
fact that FACTOR 64 enrolled a population of diabetics
with higher cardiovascular risk—when compared to our
study, the FACTOR 64 population had a greater proportion of men, an older cohort (62 vs. 55 years in our
study), a longer duration of diabetes (13.9 vs. 5.2 years),
and a higher rate of insulin use (43 vs. 22 %) [41].
Screening modalities for coronary disease

Among the screening modalities tested in our study, we
found that CAC scoring had the greatest sensitivity and
specificity for detection of CAD. The strong test characteristics of calcium scoring are unsurprising, as CAC is
by definition 100 % specific for coronary plaque and the
sensitivity is only limited by the presence of exclusively
non-calcified plaque.
In our sample, the subset whose CAD would be missed
by calcium scoring—those with coronary plaque but

Rassi et al. Cardiovasc Diabetol (2016) 15:28
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Table 4 Test characteristics of clinical data for prediction of coronary artery disease detected by coronary CTA
Definition of positive

Frequency
(total n = 98) (%)

Sensitivity
(%)

Specificity
(%)

Age ≥50 years

75 (77)

83.7

29.1

Age ≥55 years

44 (44.9)

60.5

67.3

History of hypertension, current treatment, or
SBP ≥ 140 mmHg

65 (66.3)

81.4

45.5

LDL cholesterol ≥130 mg/dL or statin therapy

65 (66.3)

76.7

41.8

Current insulin use at time of CTA

22 (22.5)

34.9

87.3

Hemoglobin A1c ≥ 8.0 %

30 (30.6)

46.5

81.8

Duration of DM > 6 years

33 (33.7)

51.2

80.0

≥1 criterion defined above
≥3 criteria defined above

Clinical variables
Age ≥50 years

Age ≥55 years

High risk clinical criteria
Hypertension
Hyperlipidemia
Insulin use
Poor glycemic control
Long duration of diabetes
Combinations of high risk clinical criteria
At least 1 high risk clinical criterion
At least 2 high risk clinical criteria
At least 3 high risk clinical criteria
At least 4 high risk clinical criteria
At least 5 high risk clinical criteria

87 (88.8)

95.3

16.4

≥2 criteria defined above

65 (66.3)

86.0

49.1

38 (38.8)

65.1

81.8

≥4 criteria defined above

15 (15.3)

27.9

94.5

8 (8.2)

16.3

98.2

5 criteria defined above

Coronary artery disease defined as the presence of any coronary artery plaque on CTA

Fig. 2 Prevalence of coronary artery disease as detected by coronary
CTA stratified by insulin use and age. The prevalence of CAD was
greater in those over age 50 and those with insulin-dependent
diabetes

without coronary calcium—represented 5 % of the total
population and 8 % of those with a calcium score of zero.
Other authors have found higher rates of coronary plaque
in such patients without any coronary calcium [42].
However, since most prior studies have demonstrated an
extremely low event rate for patients with CAC scores
of zero, it is unclear whether the presence of exclusively
non-calcified plaque is associated with any meaningful
increase in cardiovascular risk [43].
By contrast, exercise treadmill testing was insensitive,
but quite specific for the presence of coronary disease, a
conclusion that is in keeping with prior studies of ETT

Fig. 3 Prevalence of coronary artery disease as detected by coronary CTA stratified by duration of diabetes. The prevalence of CAD
increased with increasing duration of diabetes, from 26 % in those
with diabetes for 3 year or less to 67 % in those with diabetes for
6 years or longer

in diabetic populations [44–47]. This result is consistent
with our pathophysiologic understanding of exercise testing, as a positive ETT requires the presence of flow-limiting coronary disease, which implies a more advanced
coronary lesion. The proportion of subjects with nondiagnostic testing is also in-line with prior series [44, 48].
Carotid ultrasound had only modest results in both
sensitivity and specificity, suggesting that this is a less
useful test for the evaluation of possible coronary heart
disease in this population. Similar to our findings, Djaberi et al. [49] evaluated 150 asymptomatic diabetics,
using a lower CIMT cutoff of 0.62 mm, and reported a
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sensitivity and specificity of 76 and 71 %, respectively
for prediction of any coronary atherosclerosis . Other
data, mostly in non-diabetic cohorts, have varied on this
subject. Guarici and colleagues [50], in a moderate risk
group of symptomatic patients, were able to demonstrate
CIMT to be independently predictive of obstructive coronary plaque. Other series, by contrast, have not found
any association between carotid IMT and the presence
of coronary atherosclerosis by CTA [51]. While there are
data supporting the association between carotid disease
(both increased CIMT and carotid plaque) and coronary
heart disease events [52–55], the presence of carotid disease likely has a stronger association with stroke; data
from MESA support this, demonstrating that CAC was a
much stronger predictor of coronary events than carotid
ultrasound measures [56].
Carotid disease in the absence of CAD

Interestingly, almost one-third of subjects in our study
who did not have CAD were found to have carotid artery
plaque on carotid ultrasound. This represents a potentially intriguing subgroup, as these subjects are low risk—
by virtue of their absence of CAD—from a coronary
perspective but may have elevated cerebrovascular risk
[57], especially since diabetes itself is also a risk factor
for cerebrovascular disease [58]. A similar population of
patients—with carotid atherosclerosis but without coronary disease—was described in a recent paper by Cohen
et al. [59] who demonstrated that, in a cohort of 150 predominantly non-diabetic patients referred for coronary
CTA, 52 % (33 of 63) of those without any CAD on coronary CTA had carotid plaque.
The exact clinical implications of this finding, however,
remain unclear, and data are mixed as to whether carotid
plaque represents a significant cerebrovascular risk factor
in diabetics above and beyond traditional cardiovascular
risk factors, as associations between carotid plaque and
stroke often do not retain statistical significance in multivariate models or do so only in certain subsets of patients
[27, 60, 61]. Carotid atherosclerosis may also herald
atherosclerosis in other vascular beds, and this population may be at increased risk of developing incident
cardiovascular disease other than stroke. Thus, future
studies are warranted regarding the prognostic implications of having carotid plaque in the absence of coronary
atherosclerosis.
Other markers of risk

Our data also show higher prevalence of CAD in subjects on insulin therapy and an association between the
presence of CAD and both insulin use and duration of
diabetes. Subjects receiving insulin and those who had
carried a diagnosis of diabetes for a longer period of time
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had greater prevalence of CAD, and insulin use was the
most specific single clinical characteristic for the presence of coronary disease. Insulin use has previously been
associated with a greater extent of coronary disease in
diabetics [31, 62], and duration of diabetes has also been
associated with worse clinical outcomes [63]. However,
these two characteristics are rarely highlighted as part of
a practical, clinical approach to risk stratification, despite
the presence of a potential pathophysiological link and
potential clinical utility of those findings [62].
Screening in asymptomatic diabetics

Despite the inherent appeal of early detection of CAD,
studies of screening for coronary disease in asymptomatic diabetics have thus far not shown a convincing
benefit. The Detection of Ischemia in Asymptomatic
Diabetics (DIAD) study, the first large-scale, randomized
trial to assess a screening program in asymptomatic diabetics, did not find a difference in adverse cardiac outcomes between screened and unscreened subjects [9].
Importantly, though, this study screened subjects with
SPECT myocardial perfusion imaging, a test less sensitive
than coronary CTA for detection of CAD, and rates of
modern medical therapy (statins, aspirin, beta blockers,
ACE inhibitors) were high and similar in both groups.
The more recent FACTOR-64 trial addressed this
limitation, using coronary CTA to screen asymptomatic
diabetics, but similarly did not demonstrate a beneficial
effect of screening on hard cardiovascular outcomes [41].
In this case, just as with DIAD, one of the most salient
features of the trial was again the low event rate—less
than 2 % annually—which was substantially less than the
16 % event rate over 2 years that had been anticipated for
the study’s power calculation. This difference reflected
the excellent background medical therapy, with ~75 % of
study participants having an LDL cholesterol <100 mg/
dL at baseline.
According to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines,
all diabetics—and therefore all subjects in our study—
should be treated with a moderate or high-intensity statin [64]. However, statin therapy is not without adverse
effects [65–68], and it is conceivable that subjects without
coronary disease may not experience sufficient benefit of
statin therapy, although further research is required in
this area. Specifically, what the DIAD and FACTOR-64
studies did not address was whether subjects with negative screening tests might safely avoid some preventative
therapies. Within our cohort, screening with coronary
CTA identified over 50 % of subjects as having low risk for
coronary heart disease, suggesting that a significant proportion of individuals who might choose, based on their
preferences, to focus on lifestyle therapies while deferring
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pharmacological treatments. Nevertheless, further studies
are needed regarding the role of statin therapy to reduce
the lifetime risk of future cardiovascular events in individuals who do not have evidence of coronary plaque.
Limitations

Our study is limited by its small size, composed of 98
individuals. However, we examined a homogenous and
well-defined cohort, consisting only of asymptomatic
subjects with diabetes who had no known cardiovascular or renal disease. In addition, despite its small size,
our study is unique as it is the only study of which we are
aware that has correlated the findings of CAC scoring,
carotid ultrasonography, ETT and biochemical testing
against the gold standard of coronary CTA in asymptomatic individuals with diabetes. We did not incorporate
data on visceral adiposity or the relative severity of body
fat, both of which have been shown to be associated
with subclinical atherosclerosis [69, 70]. Finally, another
limitation is that our data are cross-sectional and lack
information on clinical outcomes. However, it is well
documented that CAC scoring and the presence of CAD
by CTA are strong predictors of cardiovascular events
among subjects with diabetes [31, 71–76].

Conclusion
Within this population of asymptomatic subjects with
diabetes, 56 % did not have any atherosclerotic coronary
artery disease by coronary CTA, a finding that highlights
the heterogeneity of cardiovascular risk in diabetics.
Further research is required to better delineate whether
there is any clinical role for screening programs to detect
such individuals. Such screening could be used to individualize the intensity of lifestyle and pharmacotherapy
based on risk level as well as patient preferences. When
compared to coronary CTA, screening for CAC was the
most accurate method for detection of subclinical coronary artery disease, as compared to carotid ultrasonography or exercise treadmill testing. Finally, a substantial
proportion of subjects without CAD had detectable
carotid artery plaque, and further investigation is needed
to understand both if this represents a population at
increased risk of adverse events and whether any interventions might decrease this risk.
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